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Abstract 
Aim: To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 
diabetes mellitus.
Methods: 213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, 
or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached 
patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and com-
pared to amlodipine 10 mg + ASA 100 mg (Phase B). We assessed at baseline, at the end of Phase A, and at the end 
of Phase B the levels of some new emerging biomarkers of cardiovascular risk including: high sensitivity C-reactive 
protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), myeloperoxidase (MPO), 
soluble CD40 ligand (sCDL40).
Results: Compared to baseline, at the end of Phase A, patients treated with amlodipine 5 mg + ASA 100 mg showed 
a statistically significant reduction of Hs-CRP (−15.0%), TNF-α (−21.7%), MPO (−9.7%), and sCDL40 (−15.7%), and a 
statistically significant increase of ADN (+15.0%). These values were significantly better than the ones obtained with 
amlodipine alone. Similarly, at the end of Phase B, amlodipine 10 mg + ASA significantly lowered Hs-CRP (−18.8%), 
TNF-α (−15.0%), MPO (−9.2%), and sCDL40 (−20.0%) and increased ADN (+11.8%), with a better effect compared to 
amlodipine alone.
Conclusion: All biomarkers considered were significantly improved by ASA addition. These data suggest that the use 
of ASA in primary prevention could be useful in patients with type 2 diabetes mellitus and hypertension.
Trial registration: ClinicalTrials.gov: NCT02064218
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Background
Cardiovascular diseases are the main cause of death, 
hospitalization and disability among people with type 
2 diabetes mellitus [1]. The incidence of cardiovascular 
disease in people with diabetes is more than double that 
in people without diabetes, and the mortality rate after a 
first myocardial infarction is much higher in people with 
diabetes [2, 3].
For this reason, primary prevention of cardiovascu-
lar diseases is very important in people with diabetes. 
At this regard, the Italian trial MIND-IT (The Multiple 
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Intervention in type 2 Diabetes Italy) showed that a 
multi-factorial intensive intervention in type 2 diabe-
tes is feasible and effective in clinical practice and it is 
associated with significant and durable improvement in 
glycated hemoglobin (HbA1c) and cardiovascular dis-
ease risk profile [4]. This was confirmed by the Italian 
guidelines for the treatment of type 2 diabetes mellitus 
that recommended primary prevention in patients with 
diabetes throughout changes in lifestyle, glycemic and 
lipid control, blood pressure control, and possible intro-
duction of anti-platelet therapy [5]. Also the recently 
published American Diabetes Association guidelines rec-
ommend aspirin therapy (75–162  mg/day) as a primary 
prevention strategy in patients at increased cardiovas-
cular risk, including men aged >50 years or women aged 
>60 years with, at least, one additional major risk factor 
(family history of cardiovascular disease, hypertension, 
smoking, dyslipidemia, or albuminuria) [6]. Despite the 
higher absolute risk of cardiovascular disease in these 
patients, however, there is no robust evidence that the 
use of acetylsalicylic acid (ASA) leads to a favourable 
benefits-to-risk balance [7]. The JPAD study (Japanese 
Primary Prevention of Atherosclerosis with aspirin for 
Diabetes) analyzed the effect of ASA, 81–100  mg, in 
patients with type 2 diabetes in primary prevention of 
atherosclerotic events. The risk of cardiovascular dis-
ease did not differ between the group receiving ASA and 
the one that did not, however, among individuals aged 
65 years and older, the incidence of atherosclerotic events 
was significantly lower in the group receiving ASA com-
pared with the group who did not [8]. On the other hand, 
the POPADAD trial (Prevention of progression of arte-
rial disease and diabetes) trial, conducted in patients with 
diabetes mellitus and asymptomatic peripheral arterial 
disease, did not provide evidence to support the use of 
aspirin in primary prevention of cardiovascular events 
and mortality in the population with diabetes [9].
Recently some new emerging biomarkers, including 
soluble CD40 ligand (sCD40L) and serum myeloperoxi-
dase (MPO), have been linked to a higher cardiovascular 
risk [10]. On this basis the aim of this study was to evalu-
ate the relevance of adding ASA in primary prevention in 
subjects with type 2 diabetes mellitus. To verify this, we 
evaluated ASA effects on the levels of some new emerg-
ing biomarkers of higher cardiovascular risk in patients 
with diabetes and hypertension.
Methods
Study design
This randomized, double-blind, controlled study was 
conducted at the Department of Internal Medicine and 
Therapeutics, University of Pavia, PAVIA, Italy.
The study protocol was conducted in accordance with 
the Declaration of Helsinki and its amendments, and the 
Good Clinical Practice Guidelines. It was approved by the 
each Ethical Committee and all patients provided written 
informed consent prior to entering the study. Trial regis-
tration: ClinicalTrials.gov NCT02064218.
Patients
We enrolled 213 outpatients (Table 1), aged ≥18 of either 
sex, satisfying all the following inclusion criteria:
  • overweight (body mass index between 25.0 and 
29.9 kg/m2);
  • mild to moderate hypertension defined by systolic 
blood pressure (SBP)  ≥  140  mmHg  <  180  mmHg 
and/or diastolic blood pressure (DBP) ≥  90  mmHg   
< 105 mmHg;
  • normocholesterolemic [low density lipoprotein cho-
lesterol (LDL-C) <160 mg/dl];
  • well controlled type 2 diabetes mellitus (HbA1c  ≤   
7.5%); all classes of anti-diabetic medications were 
allowed;
  • in primary prevention;
 • naïve to anti-hypertensive and anti-platelet treatment 
in order to avoid possible interactions on primary 
objective of our study.
The exclusion criteria were secondary hyperten-
sion, severe hypertension (SBP  ≥  180  mmHg or 
DBP ≥ 105 mmHg), hypertrophic cardiomyopathies due 
to etiologies other than hypertension, history of heart 
failure, history of angina, stroke, transient ischemic cere-
bral attack, coronary artery bypass surgery or myocardial 
infarction any time prior to visit 1, concurrent known 
symptomatic arrhythmia, liver dysfunction (AST or ALT 
values exceeding twofold the upper limit), creatinine 
>1.5  mg/dl, known hypersensitivity to the study drugs. 
Patients with previous gastric or duodenal bleedings 
and patients with previous intolerance to ASA were also 
Table 1 Baseline characteristics of enrolled patients
Data are presented as mean ± standard deviation.




Age (years) 57.8 ± 7.9
Smokers (M/F) 23/18
BMI (kg/m2) 27.7 ± 1.8
HbA1c (%) 6.7 ± 0.7
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excluded. Pregnant women as well as women of child-
bearing potential were excluded.
For all the study duration, no other anti-inflammatory 
drugs (NSAIDs, immunosuppressive agents, antibiotics, 
etc.) other than ASA were allowed during the 6 months 
follow-up.
Suitable subjects, identified from review of case notes 
and/or computerized clinic registers were contacted per-
sonally or by telephone.
Treatments
The patients fulfilling the inclusion criteria, were ran-
domized to amlodipine 5  mg/day, or amlodipine 
5  mg/day  +  ASA 100  mg for 3  months (Phase A); 
then, if adequate blood pressure control was reached 
(BP  <  140/90  mmHg), patients terminated the study; 
otherwise, they proceeded in Phase B of the trial, where 
amlodipine was up-titrated to 10  mg/day for further 
3  months and compared to amlodipine 10  mg  +  ASA 
100 mg (Fig. 1).
All drugs were supplied as identical, opaque, white 
capsules in coded bottles to ensure the blind status of 
the study. Randomization was done using a drawing of 
envelopes containing randomization codes prepared by 
a statistician. A copy of the code was provided only to 
the responsible person performing the statistical analy-
sis. The code was only broken after database lock, but 
could have been broken for individual subjects in cases 
of an emergency. Medication compliance was assessed by 
counting the number of pills returned at the time of spec-
ified clinic visits. At baseline, we weighed participants 
and gave them a bottle containing a supply of the study 
medication for at least 100  days. Throughout the study, 
we instructed patients to take their first dose of new 
medication on the day after they were given the study 
medication. At the same time, all unused medication was 
retrieved for inventory. All medications were provided 
free of charge.
Diet and exercise
All patients were already following a controlled-energy 
diet (near 600  kcal daily deficit) based on American 
Heart Association (AHA) recommendations [11] that 
included 50% of calories from carbohydrates, 30% from 
fat (6% saturated), and 20% from proteins, with a maxi-
mum cholesterol content of 300 mg/day and 35 g/day of 
fibre. Patients were not treated with vitamins or mineral 
preparations during the study.
For all the study duration, patients of both arms were 
encouraged to continue to follow an adequate lifestyle. 
Standard diet advice was given by a dietician and/or spe-
cialist doctor. Dietician and/or specialist doctor periodi-
cally provided instruction on dietary intake recording 
procedures as part of a behaviour modification program 
and then later used the subject’s food diaries for counsel-
ling. Individuals were also encouraged to increase their 
physical activity by walking briskly for 20–30  min, 3–5 
times per week, or by cycling.
Amlodipine 5 mg/day
Amlodipine 5 mg/day + 
acetylsalicylic acid 100 mg/day
Amlodipine 10 mg/day
Amlodipine 10 mg/day + 
acetylsalicylic acid 100 mg/day
Start Randomization 3 months 6 months
If BP ≥ 140/90 mmHg
Screening
Phase A Phase B
213 subjects
(107 males, 106 females)
110 subjects
(54 males, 56 females)
Fig. 1 Study design.
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Assessments
Before starting the study, all patients underwent an ini-
tial screening assessment that included a medical his-
tory, physical examination, vital signs, and a 12-lead 
electrocardiogram. We assessed blood pressure (BP). 
We also collected blood sample to evaluate: high sensi-
tivity C-reactive protein (Hs-CRP), adiponectin (ADN), 
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-
1β), MPO, sCDL40. All parameters were assessed at 
baseline, and after 3 months (at the end of Phase A) for 
all patients, and after further 3  months (at the end of 
Phase B only) only for patients proceeding in Phase B 
of the trial.
All plasmatic parameters were determined after a 12-h 
overnight fast. Venous blood samples were taken for all 
patients between 08.00 and 09.00 A.M. We used plasma 
obtained by addition of Na2-EDTA, 1 mg/ml, and centri-
fuged at 3,000g for 15 min at 4°C. Immediately after cen-
trifugation, the plasma samples were frozen and stored 
at −80°C for no more than 3 months. All measurements 
were performed in a central laboratory.
Blood pressure measurements were obtained from 
each patient (left arm) in the sitting position by physi-
cians blinded to treatment using a standard mercury 
sphygmomanometer (Erkameter 3000; ERKA, Bad Tolz, 
Germany) (Korotkoff I and V) with a cuff of appropri-
ate size. Blood pressure has been always measured in the 
morning before daily drug intake (i.e., at trough 22–24 h 
after dosing) and after the subject has rested 10 min in a 
quiet room. Three successive BP readings were obtained 
at 1-min intervals and averaged.
Heart rate was measured by pulse palpation for 30  s, 
just before the BP measurements.
Body weight was measured with light clothes and with-
out shoes and BMI was calculated as the weight in kg 
divided by height in m squared.
High sensitivity C-reactive protein was measured with 
use of latex-enhanced immunonephelometric assays on a 
BN II analyser (Dade Behring, Newark, Delaware, USA). 
The intra- and interassay coefficient of variations (CsV) 
were 5.7 and 1.3%, respectively [12].
Adiponectin level was determined using Enzyme-
Linked Immunosorbent Assay (ELISA) kits (B-bridge 
International, Sunnyvale, CA, USA). Intraassay CsV were 
3.6% for low-control sample and 3.3% for high-control 
sample, whereas interassay CsV were 3.2% for low-con-
trol sample and 7.3% for high-control samples, respec-
tively [13].
Tumor necrosis factor-α level was assessed using com-
mercially available ELISA kits according to manufac-
turer’s instructions (Titer-Zyme EIA kit; Assay Designs, 
Ann Arbor, MI, USA). Intraassay CsV were 4.5% for low- 
and 3.6% for high-concentration samples, whereas the 
interassay CsV were 6.0% for low and 11.8% for high-con-
centration samples, respectively [14].
We used a human cytokine 27-Bio-Plex assay kit (Bio-
Rad Laboratories, Milan, Italy), a bead-based multiplex 
immunoassay for IL-1β. This technology has the capac-
ity to measure several cytokines/cytokine receptors 
and growth factors simultaneously in small volumes of 
plasma with high accuracy and sensitivity [15]. The lower 
detection limit was 0.2–19.3  pg/mL. The samples were 
read on a Bio-Plex 200 instrument equipped with the 
software bioplex manager, version 4.1, (Bio-Rad Labo-
ratories, Hercules, CA, USA), using a five-parameter 
non-linear regression formula to compute sample con-
centrations from the standard curves.
Myeloperoxidase was assessed using commercially 
available ELISA kits according to manufacturer’s instruc-
tions (R & D Systems, Minneapolis, MN, USA). The intra- 
and interassay CsV were 7.7 and 8.3%, respectively [16].
Soluble CD40 ligand was assessed using commercially 
available ELISA kits according to manufacturer’s instruc-
tions (R & D Systems, Minneapolis, MN, USA). The intra- 
and interassay CsV were 4.5 and 6.0%, respectively [17].
Statistical analysis
Data are expressed as mean ±  standard deviation (SD). 
The statistical analysis of the data was performed by the 
statistical analysis software (SAS) system, version 6.12 
(SAS Institute, Inc., Cary, NC, USA). The differences 
between the two groups in baseline characteristics were 
analyzed by the two-tailed Student’s t test. Interven-
tion effects were adjusted for additional potential con-
founders (sex, smoking status, and age) using analysis 
of covariance (ANCOVA). Continuous variables were 
tested using a two-way repeated measures analysis of 
variance (ANOVA). Differences between baseline and 
3-months of treatment in each group were analyzed with 
the Wilcoxon signed rank test [18]. Non-parametric tests 
were also employed in the statistical analysis of the data, 
because some data were not normally distributed (Kol-
mogorov–Smirnov test). The statistical significance of the 
independent effects of treatments on the other variables 
was determined using ANCOVA taking the baseline level 
of each parameter as a covariate.
Findings of p < 0.05 were considered significant. Con-
sidering as clinically significant a difference of at least 
10% compared with the baseline and an alpha error of 
0.05, the actual sample size was adequate to obtain a 
power higher than 0.80 for all measured variables.
Results
Study sample
We enrolled 213 patients; 107 were randomized to 
amlodipine 5  mg, and 106 to amlodipine 5  mg  +  ASA 
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100  mg; 110 patients did not reach an adequate blood 
pressure control and continued in the second phase of 
the study with up-titration to amlodipine 10 mg (54 sub-
jects) or amlodipine 10 mg + ASA 100 mg (56 subjects). 
Five patients did not complete the first phase of the study 
(four patients in amlodipine 5 mg group and one patient 
in amlodipine 5  mg  +  ASA group) and three patients 
(two patients in amlodipine 10 mg group and one patient 
in amlodipine 10 mg + ASA group) did not complete the 
second phase of the trial. The reason for premature with-
drawal were: lost to follow-up, peripheral edema, epigas-
tralgy, withdrawal of informed consent. At baseline, no 
differences between the two groups were recorded. A list 
of anti-diabetic treatments taken at the beginning of the 
study was reported in Table 2.
Blood pressure
We recorded a decrease of SBP (−6.5% with amlodipine 
5 mg, −5.9% with amlodipine 5 mg + ASA, −13.2% with 
amlodipine 10 mg, −13.5% with amlodipine 10 mg + ASA). 
A similar trend was observed for DBP (−8.2% with 
amlodipine 5  mg, −9.4% with amlodipine 5  mg  +  ASA, 
−14.8% with amlodipine 10 mg, −15.1% with amlodipine 
10  mg  +  ASA). No differences between amlodipine or 
amlodipine + ASA were recorded (Tables 3, 4).
New markers of cardiovascular risk
After 3  months of therapy, no variations of the above 
cited markers were recorded with amlodipine alone. 
Patients treated with amlodipine 5  mg +  ASA 100  mg, 
instead, showed a reduction of MPO, and sCDL40, com-
pared to baseline (−9.7 and −15.7%, respectively), and to 
amlodipine alone (−5.1 and −13.6%). One hundred and 
seven patients continued the study, and were up-titrated 
to amlodipine 10  mg  +  ASA 100  mg or to amlodipine 
10 mg alone. We observed a decrease of MPO (−6.4% for 
amlodipine alone, and −15.0% for amlodipine  +  ASA), 
and sCDL40 (−5.1% for amlodipine alone, and −24.1% 
for amlodipine  +  ASA) in both groups compared 
to baseline, even if values recorded with amlodipine 
10  mg +  ASA were lower than the ones recorded with 
amlodipine 10 mg alone (−9.2 and −20.0%, respectively) 
(Tables 3, 4).
Inflammatory markers
We did not record any variations of inflammatory mark-
ers after 3  months of amlodipine monotherapy. In the 
group treated with amlodipine 5  mg  +  ASA 100  mg, 
instead, there was a reduction of Hs-CRP (−15.0%), and 
TNF-α (−21.7%), and an increase of ADN (+15.0%) com-
pared to baseline, and to amlodipine alone (−10.5, −14.3 
and +9.7%, respectively). Regarding IL-1β, it decreased 
with amlodipine 5  mg  +  ASA 100  mg compared to 
baseline (−50.0%), but no differences were recorded 
compared to amlodipine alone. In patients continuing 
the study, we recorded a decrease of Hs-CRP (−20.0% 
with amlodipine and −35.0% with amlodipine +ASA), 
and TNF-α (−13.1% with amlodipine and −26.1% with 
amlodipine  +  ASA), and an increase of ADN (+11.7% 
with amlodipine and +22.1% with amlodipine  +  ASA) 
compared to baseline. Values recorded with amlodi-
pine 10  mg +  ASA were better than the ones recorded 
with amlodipine 10  mg alone (−18.8, −15 and +11.8%, 
respectively). Regarding IL-1β, it decreased compared 
to baseline only with amlodipine 10 mg + ASA (−50%) 
(Tables 3, 4).
Adverse events
No significant serious adverse events were reported. We 
recorded six episode of epistaxis, and four episodes of 
epigastralgy in patients taking ASA, and four episodes of 
peripheral edema in amlodipine 10 mg groups; all events 
were reported as mild.
Table 2 Anti-diabetic drugs taken before randomisation





Lifestyle 5 (2.34) 2/3)
Sulfonylureas, n (%) (M/F) 42 (19.7) (18/24)
 Glyburide 3 (7.1) (1/2)
 Glimepiride 17 (40.5) (10/7)
 Gliclazide 22 (52.4) (12/10)
Biguanides, n (%) (M/F) 153 (71.8) (71/82)
 Metformin 153 (100) (71/82)
Glinides, n (%) (M/F) 32 (15.0) (17/15)
 Repaglinide 32 (100) (17/15)
α-glucosidase inhibitors, n (%) (M/F) 33 (15.5) (14/19)
 Acarbose 33 (100) (14/19)
Thiazolidinediones, n (%) (M/F) 28 (13.1) (15/13)
 Pioglitazone 24 (85.7) (12/12)
 Rosiglitazone 4 (14.3) (3/1)
DPP-4 inhibitors, n (%) (M/F) 33 (15.5) (17/16)
 Sitagliptin 12 (36.4) (6/6)
 Vildagliptin 10 (30.3) (6/4)
 Saxagliptin 7 (21.2) (3/4)
 Linagliptin 4 (12.1) (2/2)
GLP-1 analogs, n (%) (M/F) 15 (7.0) (8/7)
 Exenatide 10 (66.7) (7/3)
 Liraglutide 5 (33.3) (2/3)
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Discussion
We observed that the addition of ASA to amlodipine 
therapy in patients with diabetes was effective, in pri-
mary prevention, in reducing some inflammatory and 
new emerging biomarkers in cardiovascular risk strati-
fication, suggesting a favourable effects of ASA in this 
kind of patients. In particular, our data showed a reduc-
tion of Hs-CRP not reported by Vaucher et al. [19]. These 
Authors reported that low-dose aspirin for cardiovas-
cular prevention does not impact plasma pro-inflam-
matory cytokines and Hs-CRP levels, however, in their 
study, only a small portion of the studied population was 
affected by diabetes, while our population was all affected 
by diabetes.
In our study we also observed a reduction of MPO 
and sCDL40 in patients treated with ASA. Reduction of 
Table 3 Data of patients completing Phase A of the trial
Data are expressed as mean ± standard deviation.




Parameters Amlodipine 5 mg Amlodipine 5 mg + ASA 100 mg
Baseline 3 months Baseline 3 months
N 107 103 106 105
Sex (M/F) 54/53 51/52 53/53 53/52
Smokers (M/F) 12/10 11/10 12/9 12/8
SBP (mmHg) 156.4 ± 9.4 145.2 ± 8.4* 153.6 ± 9.0 146.1 ± 8.8*
DPB (mmHg) 95.9 ± 5.5 88.9 ± 4.1* 97.2 ± 5.9 87.7 ± 3.9*
Hs-CRP (mg/l) 2.1 ± 0.9 1.9 ± 0.7 1.9 ± 0.7 1.7 ± 0.5*^
ADN (μg/ml) 5.4 ± 1.2 5.6 ± 1.2 5.2 ± 1.0 6.2 ± 1.8*^
TNF-α (pg/ml) 2.4 ± 0.9 2.1 ± 0.7 2.3 ± 0.8 1.8 ± 0.5*^
IL-1β (pg/ml) 0.6 ± 0.5 0.5 ± 0.3 0.6 ± 0.5 0.3 ± 0.2*
MPO (ng/ml) 780.1 ± 220.3 740.3 ± 220.4 776.5 ± 218.5 702.7 ± 114.4*^
sCDL40 (pg/ml) 1254.4 ± 110.2 1231.3 ± 102.1 1260.7 ± 119.5 1064.5 ± 92.9*^
Table 4 Data of patients entering the Phase B of the trial
Data are expressed as mean ± standard deviation.





Parameters Amlodipine 10 mg Amlodipine 10 mg + ASA 100 mg
Baseline 3 months Baseline 3 months
N 54 52 56 55
Sex (M/F) 25/29 24/28 29/27 28/27
Smokers (M/F) 4/3 4/3 5/3 5/3
SBP (mmHg) 153.7 ± 9.1 134.8 ± 6.1° 154.2 ± 9.2 134.2 ± 5.9°
DPB (mmHg) 95.1 ± 5.2 82.5 ± 3.2° 96.8 ± 5.7 82.2 ± 3.1°
Hs-CRP (mg/l) 2.0 ± 0.8 1.6 ± 0.5* 2.0 ± 0.8 1.3 ± 0.4°^
ADN (μg/ml) 5.1 ± 1.1 6.0 ± 1.5* 5.3 ± 1.2 6.8 ± 1.9°^
TNF-α (pg/ml) 2.5 ± 0.8 2.0 ± 0.6* 2.2 ± 0.7 1.7 ± 0.4°^
IL-1β (pg/ml) 0.5 ± 0.8 0.5 ± 0.3 0.5 ± 0.4 0.3 ± 0.2*
MPO (ng/ml) 775.2 ± 219.5 728.1 ± 217.3* 774.2 ± 216.2 661.2 ± 112.3°^
sCDL40 (pg/ml) 1252.8 ± 118.9 1198.4 ± 99.7* 1268.5 ± 118.2 958.3 ± 82.4°^
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sCDL40 was reported also by Rosiak et al. that reported 
a significant reduction of Hs-CRP, sCD40L, and interleu-
kin-6 with ASA [20].
Differently from what reported in literature [21, 22] 
where, in patients with diabetes, age proved to be the 
most important predictive factor of laboratory response 
to ASA therapy, we did not record different effects of 
ASA according to different age; this is probably due to 
the fact that, in our population, age standard deviation 
was very low, suggesting a homogeneous data. The anti-
inflammatory action observed in our study can be only 
partially explained by blood pressure reduction, because 
amlodipine dose was identical in both arms. Moreo-
ver, we chose to use amlodipine as anti-hypertensive 
agent because, from the evidence published in literature, 
amlodipine proved to be neutral on Hs-CRP, both used 
alone [23], or in addition to atorvastatin [24], even if it 
increased adiponectin both in combination with atorvas-
tatin [24] and olmesartan [25]. All data collected suggest 
a protective effect linked to ASA use in primary preven-
tion in patients with diabetes.
Regarding the mechanism of action throughout ASA 
acts, it is largely known that ASA is the archetypal non 
steroidal anti-inflammatory drug found to inhibit the 
cyclooxygenase (COX II) pathway of arachidonic acid 
metabolism [26], being anti-inflammatory at 1  g dose 
[27], but cardioprotective at lower doses (75–150  mg/
day) through the inhibition of platelet-derived thrombox-
ane (Tx) A2 [28, 29]. ASA also inhibits pathways inher-
ent to innate immunity including the production of TxA2 
[30], which is suggested to facilitate the polymorphonu-
clear leukocyte (PMN)-platelet interaction that leads to 
PMN transmigration into inflamed tissues [31]. Moreo-
ver, ASA triggers the synthesis of novel lipid metabolites 
that directly halt leukocyte trafficking and elicit pro-
resolution effects [32]. In addition, there is evidence that 
ASA down-regulates pro-inflammatory signaling path-
ways including NF-κB [33]. This suggests that ASA may 
be anti-inflammatory at levels used in cardio-protection. 
This was confirmed by Morris et al. [34] that showed that 
ASA dampens innate immuno-mediated responses in 
humans by triggering 15-epi-lipoxin A4 from endothelial 
COX2 expressed in response to local injury, which subse-
quently prevents leukocyte accumulation to sites of tissue 
injury in an NO-dependent manner.
Of course our study has some limitations: for exam-
ple, we evaluated only some inflammatory parameters 
and some new markers of cardiovascular disease, focus-
ing our attention on a few of them. Moreover, it would be 
interesting to verify if the reduction of these biomarkers 
will have an impact on the reduction of cardiovascular 
events, but, to assess this, longer studies are needed.
Conclusions
The addition of ASA to amlodipine gave a better 
improvement of inflammatory parameters compared to 
amlodipine alone, suggesting a role of ASA in reducing 
inflammation and endothelial damage independently 
from the blood pressure reduction. These data sug-
gest that the use of ASA in primary prevention could 
be useful in patients with type 2 diabetes mellitus and 
hypertension.
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